Related Experiment Video
Updated: Jun 6, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis
Thomas Schmitt1, Eva Keller, Sascha Dietrich
1Department of Internal Medicine V, Heidelberg University Clinics, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Thomas.Schmitt@med.uni-heidelberg.de
Marine Drugs
|December 1, 2010
Summary
Trabectedin shows efficacy in advanced soft tissue sarcoma (STS) patients, even those heavily pre-treated. This drug offers prolonged progression-free and overall survival with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
- Medical Therapeutics
Background:
- Soft tissue sarcoma (STS) is a group of rare malignancies with frequent metastasis.
- Advanced STS often requires treatment beyond initial surgery, with limited options after standard chemotherapy failure.
Purpose of the Study:
- To evaluate the efficacy and safety of trabectedin in patients with advanced STS.
- To assess outcomes in a heavily pre-treated STS patient population receiving trabectedin.
Main Methods:
- Retrospective analysis of 25 STS patients treated with trabectedin (2007-2010).
- Assessment of treatment response using RECIST criteria.
- Evaluation of progression-free survival (PFS) and overall survival (OS).
Main Results:
- Low objective response rate (1 partial remission, 10 stable disease).
- Significantly prolonged median PFS (7.7 vs 2.1 months) and OS (12.13 vs 5.54 months) in responders vs. non-responders.
- 3-month and 6-month PFS rates of 58% and 37%, respectively.
- Manageable side effects, with dose reductions in 5 patients.
Conclusions:
- Trabectedin is an effective treatment for advanced STS, particularly in heavily pre-treated patients.
- The drug demonstrates a favorable safety profile with manageable adverse events.
- Trabectedin offers survival benefits in STS patients who have failed prior chemotherapy regimens.
